Latest Commercial Operations News

Talga Group has begun commercial deliveries of its Talnode®-C battery anode to Nyobolt, marking a key revenue milestone and advancing its European supply ambitions. The 3,000-tonne offtake deal sets the stage for Talga's planned commercial-scale anode plant, with further customer negotiations underway.

Saluda Medical has obtained FDA approval for its CAP24 surgical paddle lead, a first-of-its-kind device designed for closed-loop spinal cord stimulation, poised to broaden its US market reach and engage new surgical specialties.

Calix's subsidiary Leilac has locked in a paid engineering study with an East Asian cement producer, advancing its commercial cement decarbonisation technology without capital outlay. This complements its recent Indian partnership and signals a strategic pivot to capital-light projects.

Mesoblast has drawn US$50 million from a new five-year facility that reduces its interest burden and retires expensive short-term debt, strengthening its financial position ahead of commercial expansion.

Great Divide Mining Ltd (ASX: GDM) has received its first cash payment of USD 78,480.35 from gold concentrate sales at its Challenger Gold Mine, marking a key milestone in its transition from explorer to producer within three years of listing.

Great Divide Mining Ltd (ASX: GDM) has received its inaugural cash payment from concentrate sales under a 12-month offtake agreement, marking a key step from exploration to production at its Challenger Gold Mine.

Strike Energy’s South Erregulla Power Station has completed major construction and started commissioning, advancing toward its October 2026 target for commercial operation.

Tetratherix Limited (ASX:TTX) has launched a $2 million share purchase plan offering eligible Australian and New Zealand shareholders the chance to buy shares at a 2% discount to recent trading prices. The non-underwritten SPP opens on 4 June and closes on 18 June 2026.

ImpediMed has revamped its leadership with two new commercial roles and reported encouraging sales momentum for its SOZO device. The company is advancing clinical trials and expanding its presence in cancer survivorship, weight management, and heart health sectors.

A US court has dismissed Identitii's patent infringement claim against JPMorgan Chase, citing patent ineligibility. Identitii plans to appeal, while its core business remains unaffected.

New Talisman Gold Mines boosted revenue by 121% to NZ$53,000 but posted a $2.26 million net loss as it commissioned a processing plant and secured key commercial agreements.

PolyNovo has completed its pivotal US clinical trial report for NovoSorb BTM and adjusted its FDA Premarket Approval submission timeline to late 2026 to incorporate updated regulatory requirements and additional data.